CapsoVision Raises Capital and Refocuses Colon Capsule Strategy

CapsoVision, Inc. ( (CV) ) has provided an announcement.

On March 16, 2026, CapsoVision, Inc. raised approximately $14 million in a private placement of 2,867,089 common shares at a 5% discount to the prior closing price, with the deal limited to accredited investors and supported by a registration rights agreement for future resale. The company plans to deploy the proceeds for general corporate purposes and pipeline advancement, reported preliminary 2025 revenue of $13.6 million and year-end cash of about $10.1 million, and reaffirmed its focus on continued product innovation and disciplined execution.

Also on March 16, 2026, CapsoVision decided to halt pursuit of FDA clearance for its first-generation CapsoCam Colon following regulators’ questions on image processing and study design, redirecting resources to a second-generation capsule with improved imaging and AI and an expanded pivotal study targeting roughly 800 U.S. patients. As of the latest update, more than 500 patients had been enrolled in this study, with a new 510(k) submission for the upgraded CapsoCam Colon expected in the third quarter of 2026.

The company is simultaneously advancing a novel, visual, capsule-based approach to pancreatic cancer screening using its CapsoCam UGI system, aiming to define diagnostic criteria through a planned U.S. study of about 90 patients starting in the second quarter of 2026. An earlier application for FDA Breakthrough Device Designation was not approved because the device lacked defined diagnostic criteria, and CapsoVision now intends to reapply once new clinical data are available, positioning the program as a potential supplement to its regulatory pathway for early pancreatic cancer detection.

The most recent analyst rating on (CV) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on CapsoVision, Inc. stock, see the CV Stock Forecast page.

Spark’s Take on CV Stock

According to Spark, TipRanks’ AI Analyst, CV is a Neutral.

The score is weighed down primarily by weak financial performance (losses, negative equity, and negative operating/free cash flow) and a bearish technical setup (below key moving averages with negative MACD). Positive FDA-related product/regulatory initiatives provide some upside, while valuation data is insufficient to materially improve the rating.

To see Spark’s full report on CV stock, click here.

More about CapsoVision, Inc.

CapsoVision, Inc. is a commercial-stage medical technology company focused on advanced imaging and AI-enabled capsule endoscopy solutions for gastrointestinal disease detection and screening. Its flagship product, CapsoCam Plus, is a wire-free panoramic capsule endoscope for small bowel visualization, and its pipeline includes CapsoCam Colon for non-invasive colon imaging and polyp detection, as well as expansion into esophageal and pancreatic indications.

Average Trading Volume: 330,431

Technical Sentiment Signal: Hold

Current Market Cap: $289.5M

Learn more about CV stock on TipRanks’ Stock Analysis page.